| Date | Title | Description |
| 31.03.2026 | Laigo Bio Secures €17M: SureTACs Platform Targets Cancer, Autoimmune Diseases | Laigo Bio secured €17M seed funding for its SureTACs platform. The biotech pioneers precision membrane protein degradation. Funds will accelerate oncology programs to the clinic. They also advance autoimmune and immunology candidates. The i... |
| 31.03.2026 | Laigo Bio: €17 Million Raised For Biotech Developing SureTACs Precision Protein Degradation Platform | Laigo Bio, a Netherlands-based biotech company developing targeted protein degradation therapies, has completed the final close of its oversubscribed seed financing round, bringing the total raised to €17 million.
The latest tranche include... |
| 23.03.2026 | Laigo Bio Closes €17M Seed Funding | Laigo Bio, an Utrecht, The Netherlands-based biotech company, closed the second close of its seed financing round, securing an additional €5.5m, bringing the total raised to €17m.
This latest investment comes from new co-lead investor Biova... |
| 04.12.2025 | Targeting the “undruggable”: Laigo Bio secures €11.5 million to advance its SureTAC protein degradation platform | Laigo Bio, an Utrecht-based company pioneering novel and highly differentiated therapies using its proprietary SureTAC precision membrane protein degradation platform, has successfully raised €11.5 million in Seed financing.
The funding rou... |
| 13.11.2025 | Italy's Angelini Ventures opens SG office to grow Asia biotech portfolio | Angelini Ventures, the corporate venture arm of Italy’s family-owned Angelini Industries, has officially launched its first Asian office in Singapore’s CBD, according to a company statement. The office will serve as a regional hub for biote... |
| 28.10.2025 | CoMind Technologies: $102.5 Million Secured To Improve Brain Monitoring | UK-based medtech firm CoMind Technologies Limited has raised $102.5 million in a funding round aimed at transforming how critically ill patients’ brains are monitored. The round was led by Plural with participation from existing backers inc... |
| 23.10.2025 | Adcytherix: €105 Million Series A Raised For Advancing Antibody-Drug Conjugate Pipeline And Novel Payload Platform | Adcytherix, a biopharmaceutical company pioneering the design and development of novel antibody-drug conjugates (ADCs), announced the completion of a €105 million (US$122 million) Series A financing round. The funding will accelerate the co... |
| 20.10.2025 | Non-Invasive Brain Monitoring Pioneer CoMind Secures Over $100M | CoMind, a London-based startup, secured over $100 million in funding for its groundbreaking non-invasive brain monitoring technology. Their laser-based system accurately tracks cerebral blood flow and intracranial pressure, eliminating the ... |
| 20.10.2025 | No drill required: London’s CoMind raises €85 million to replace invasive brain monitoring | CoMind, a British neurological HealthTech startup, has secured over €85 million in total funding as it scales its neuromonitoring technology that measures critical brain parameters without the need for drilling into the skull.
The company’s... |
| 20.10.2025 | Non-drill brain monitoring startup CoMind raises over $100M | A UK startup which is developing brain monitoring and treatment technology which avoids drilling a hole into a patient’s skull has raised more than $100m in funding in total, it has announced.
Led by “generational founder” James Dacombe, th... |
| 20.10.2025 | CoMind Raises $60M in Funding | CoMind, a London, UK-based neurotechnology company developing breakthrough optical sensing technology to revolutionise brain monitoring and treatment, raised $60m in funding.
The round was led by Plural, with participation from existing inv... |
| 16.10.2025 | With its notable €105 million raise, French BioTech startup Adcytherix looks to tackle cancer with novel ADC | Marseille-based Adcytherix, a biopharmaceutical company developing novel and proprietary antibody drug conjugates (ADC), has raised €105 million in a Series A financing round to advance its lead candidate and treat high unmet need diseases
... |
| 06.10.2025 | Dirty Data, Clean Decisions: What’s Really Shared at Venture Intelligence Day | Prague, Czech Republic ~
Company:
Venture capital has no shortage of conferences. What’s rarer are gatherings where operators compare playbooks, not just portfolios. On October 29–30, Vestberry’s Venture Intelligence Day (VID) returns to Pr... |
| 03.10.2025 | Serenis Raises $12M in Follow-On Funding | Serenis, a Milan, Italy-based company dedicated to improving access to mental health and wellbeing services, received $12M in funding.
The round was led by Angelini Ventures and CDP Venture Capital.
The company intends to use the funds to e... |
| 12.07.2025 | Swiss Biotech Secures Major Funding for Advanced Cancer Treatments | Swiss biotech firm NUCLIDIUM secured €84 million in Series B funding. This significant capital injection propels its proprietary copper-based theranostic platform. The company targets advanced cancer diagnosis and treatment. Funds will acce... |
| 11.07.2025 | NUCLIDIUM raises €84M Series B to advance copper-based cancer therapies | NUCLIDIUM, a Swiss clinical-stage biotechnology company pioneering the development of next-generation copper-based radiopharmaceuticals for the diagnosis and treatment of cancer, has raised €84 million Series B funding.
Leveraging copper is... |
| 10.07.2025 | Swiss BioTech platform NUCLIDIUM raises €84 million for the diagnosis and treatment of cancer | Basel-based NUCLIDIUM, a clinical-stage radiopharmaceutical company developing a proprietary copper-based theranostic platform, today announced the successful closing of its Series B financing round, raising €84 million.
The round was led b... |
| 10.07.2025 | Nuclidium Raises €84M in Series B Funding | Nuclidium, a Basel, Switzerland-based clinical-stage radiopharmaceutical company developing a proprietary copper-based theranostic platform, raised €84M in Series B funding
The round was co-led by Angelini Ventures, Kurma Growth Opportuniti... |
| 10.07.2025 | CHF 79 million to advance Nuclidium’s copper-based radiopharmaceutical platform |
NUCLIDIUM’s differentiated platform links tumor-targeting molecules with copper isotopes – Copper-61 for diagnostics and Copper-67 for therapeutics – to address current limitations in radiotheranostics, such as suboptimal clinical efficacy... |
| 28.05.2025 | To develop novel therapies for cardiomyopathy, Nuevocor raised $45 M Series B funding | The Singapore-based IND-stage biotechnology startup Nuevocor, which is working to find treatments for cardiomyopathies caused by aberrant mechanobiology, has successfully closed a $45 million Series B funding round.
Nuevocor said in a state... |
| 17.05.2025 | Therini Bio Secures $39 Million to Combat Neurodegenerative Diseases | In the ever-evolving landscape of biotechnology, Therini Bio, Inc. has made headlines by securing an additional $39 million in Series A financing. This funding is a beacon of hope for those grappling with neurodegenerative diseases. Based i... |
| 15.05.2025 | Therini Bio Raises Additional $39M in Series A Financing | Therini Bio, Inc., a Sacramento, CA-based clinical-stage biotech company developing fibrin-targeting immunotherapies for neurodegenerative diseases driven by vascular dysfunction raised $39m in Series A extension financing.
The extension fi... |
| 07.05.2025 | Nuevocor's $45 Million Leap: A New Dawn for Cardiomyopathy Treatment | In the world of biotechnology, every dollar counts. A recent infusion of $45 million into Nuevocor, a Singapore-based company, is more than just a financial boost. It’s a lifeline for patients grappling with cardiomyopathies, particularly t... |
| 06.05.2025 | Nuevocor Closes US$45 Million Series B Financing for Clinical Development of Novel Mechanobiology-Centered Therapy for Cardiomyopathy | – Round co-led by new investors, Kurma Partners and Angelini Ventures, with significant participation from existing investors EDBI, ClavystBio, and Boehringer Ingelheim Venture Fund
– Proceeds will support the Phase 1/2 clinical trial of le... |
| 06.05.2025 | SG biotech startup Nuevocor raises $45m to help heart failure patients | Singapore-based biotech company Nuevocor has raised $45 million in a Series B funding round to advance the treatment for patients with cardiomyopathies, a form of heart disease that could lead to heart failure, according to a statement on T... |
| 29.04.2025 | Therini Bio Announces Positive Phase 1a Trial Results Evaluating THN391 for Neurodegenerative Diseases | Sacramento, April 29, 2025 (GLOBE NEWSWIRE) – Therini Bio, Inc., a clinical-stage biotech company developing fibrin-targeting immunotherapies for neurodegenerative diseases driven by vascular dysfunction today announced positive results fro... |
| 28.01.2025 | Nobi Raises €35M in Series B Financing | Nobi, an Antwerpen, Belgium-based AgeTech company, raised €35M in Series B funding.
The round was co-led by Angelini Ventures and Nexus NeuroTech Ventures, with participation from 15th Rock, and existing investors EQT Health Economics and E... |
| 26.03.2024 | Nouscom secures additional funding from Angelini Ventures |
Based in Basel, Nouscom is a clinical stage immune-oncology company developing off-the-shelf and personalized cancer vaccines based on its proprietary viral vector platform, which has the capacity to encode for large payloads of neoantigen... |
| 21.10.2022 | Angelini Industries Launches Angelini Ventures With EUR 300M | Paolo Di Giorgio, Chief Executive Officer, Angelini Ventures
Angelini Industries, a Rome, Italy-based multi-sector Italian industrial group, announced the launch of Angelini Ventures, a corporate venture capital initiative, with a €300M cap... |
